Immune Response after a Single Dose of the 2010/11 Trivalent, Seasonal Influenza Vaccine in HIV-1–Infected Patients and Healthy Controls

REFERENCES

• Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immuno-genicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV uninfected adults. Clin Infect Dis. 2011;52:138–146.
   PubMed Web of Science ®Google Scholar
• Launay O, Desaint C, Durier C, et al. Safety and immu-nogenicity of a monovalent 2009 influenza A/H1N1 v vaccine adjuvanted with ASO3A or unadjuvanted in HIV-infected adults: A randomized, controlled trial. J Infect Dis. 2011;204:124–134.
   PubMed Web of Science ®Google Scholar
• Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24:2187–2192.
   PubMed Web of Science ®Google Scholar
• Yanagisawa N, Maeda K, Ajisawa A, et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine. 2011;29: 5697–5698.
   Web of Science ®Google Scholar
• Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pan-demic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29:1359–1363.
   PubMed Web of Science ®Google Scholar
• Bickel M, Wieters I, Khaykin P, et al. Low rate of serocon-version after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS. 2010;24:F31—F5.
   Web of Science ®Google Scholar
• Cooper C, Klein M, Walmsley S, et al. High-level immu-nogenicity is achieved vaccine with adjuvanted pan-demic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials. 2012;13(1):23–32.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Sali M, et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine. 2011;29:2836–2839.
   PubMed Web of Science ®Google Scholar
• Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25:177–183.
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248–256.
   PubMed Web of Science ®Google Scholar
• Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (Hi Ni) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6:e16496.
   PubMed Web of Science ®Google Scholar
• Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic Hi Ni influenza vaccine, in HIV-1-infected patients. Vac-cine. 2011;29:1359–1363.
   PubMed Web of Science ®Google Scholar
• Cooper CL. Pandemic H1N1 2009 influenza and HIV: A review of natural history, management and vaccine immu-nogenicity. Curr Opin Infect Dis. 2012;25(1):26–35.
   PubMed Web of Science ®Google Scholar
• Peters PJ, Skarbinski J, Louie JK, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1): United States, spring and summer 2009. Clin Infect Dis. 2011;52(Suppl 1):S183–188.
   PubMed Web of Science ®Google Scholar
• Ormsby CE, de la Rosa-Zamboni D, Vazquez-Perez J, et al. Severe 2009 pandemic influenza A (Hi Ni) infection and increased mortality in patients with late and advanced HIV disease. AIDS. 2010;25:435–439.
   Web of Science ®Google Scholar
• Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pan-demic Hi Ni influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52(1):122–127.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Iverson E, Defang G, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (Hi Ni) vaccine among HIV-infected and HIV-uninfected adults. Vaccine. 2011;29:3183–3191.
   PubMed Web of Science ®Google Scholar
• Chadha MK, Fakih M, Muindi J, et al. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate. 2011;71(4):368–372. doi: 10.1002/pros.21250.
   PubMed Web of Science ®Google Scholar
• Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24(8)1127–1134.
   Web of Science ®Google Scholar
• Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determi-nation of serum antibodies against swine-origin influenza A virus H1 N1/09 by immunofluorescence, haemaggluti-nation inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol lmmunol. 2010;199: 117–121.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organisation manual on animal influ-enza diagnosis and surveillance. 2009. WHO/CDS/CSR/ NCS/2002.5. http://www.who.int/vaccine_research/dis-eases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf. Accessed August 17, 2012.
   Google Scholar
• US Food and Drug Administration. Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegula-toryInformation/GuidancesNaccines/ucm091985.pdf. Accessed August 17, 2012.
   Google Scholar
• Siegrist CA, van Delden C, Bel M, et al. Higher mem-ory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS One. 2012;7(7):e40428.
   PubMed Web of Science ®Google Scholar
• Walker WT, de Whalley P, Andrews N, et al. Hi Ni Antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reac-togenicity of subsequent seasonal influenza vaccine: A multi-center follow-on study. Clin Infect Dis. 2012;54(5):661–669.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, lwatsuki-Horimoto K, Adachi E, et al. Improved neutralizing antibody response in the second season after a single dose of pandemic (Hi Ni) 2009 influenza vaccine in HIV-1-positive adults [published online ahead of print April 10, 2012]. Vaccine. 2012;30(26):3819–3823.
   PubMed Web of Science ®Google Scholar
• Cooper C, Thorne A; Canadian HIV Trials Network Ctn Influenza Vaccine Research Group. Vitamin D supple-mentation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults. HIV Clin Trials. 2011;12(5):275–276.
   PubMed Web of Science ®Google Scholar